IPX · IperionX

The thesis

IperionX's titanium-powder output rose to 8.7 tons in the September quarter, but the company reported no revenue in fiscal 2026 and has not secured financing for its Titan mine. The shares are more likely to lag the S&P 500 than lead it over the next three months. The December-quarter cash report, expected around 30 January 2027, is the next scheduled test of customer receipts, and a Titan financing announcement would be the larger event.

The shares closed at $14.65 on 12 November 2026, 76.2% below the 52-week intraday high of $61.45 set on 26 January 2026, and down 37.8% over three months. The price already reflects a market that doubts the funding path: Titan development capital of US$381.3 million compares with US$63.0 million of cash at 30 September 2026.

The 29 October 2026 quarterly report stated 8.7 tons of hydrogen-assisted metallothermic reduction (HAMR) titanium powder produced, against 1.4 tons in the June quarter, and furnace capacity validated above the 200 tons-per-year target run-rate. MarketBeat reported that the shares closed at $17.04 on 29 October 2026 and opened at $14.99 on 30 October 2026, a gap down of about 12%, with no cause stated.

Bullish and bearish views on IperionX Limited

The bull case on IperionX Limited (IPX), in brief: production stepped up. The bear case: no revenue after five years.

Bull case

• Production stepped up. The company's 29 October 2026 quarterly report showed 8.7 tons of HAMR powder produced, up from 1.4 tons in the June quarter. It ended the period with 19 tons of finished powder inventory.
• Capacity validated above target. The same report said HAMR furnace capacity was validated above the 200 tons-per-year annualized run-rate target. The GenX platform was validated at an equivalent of about 100 tons per year, with integration under way and no date given.
• Liquidity is larger. Cash was US$63.0 million at 30 September 2026, up from US$35.2 million at 30 June 2026. Total available liquidity was about US$96.7 million, including US$33.7 million of remaining obligated, reimbursable US government funding.
• Army work is contracted. Task Order 2 carries a US$18.5 million base value and a US$25.4 million maximum with options, per the company's 31 August 2026 release.
• Directors bought in July. The quarterly report says directors bought about US$1.9 million of shares on-market in July 2026.
• Analyst targets sit far above the price. MarketBeat on 30 October 2026 listed six Buy ratings, one Sell and an average target of $42.

Bear case

• No revenue after five years. The fiscal 2026 annual report (Form 20-F, filed 29 September 2026) shows no revenue in fiscal 2026 or the four prior financial years. The net loss was US$66.8 million, against US$35.3 million in fiscal 2025.
• Titan financing is still open. The 29 October 2026 report describes no financing transaction. The 4 June 2026 feasibility study put development capital at US$381.3 million, many times the cash on hand.
• Cash burn continues. Net operating cash outflow was US$12.6 million in the September quarter, after US$11.9 million in the June quarter and US$45.0 million for fiscal 2026.
• Dilution risk is live. The July placement of 2,275,000 American depositary shares (ADS) priced at US$21.98. The $14.65 close on 12 November 2026 is well below that price, so a new raise would price lower.
• Shares sit under both averages. The 50-day average is $16.85 and the 200-day average is $28.60 as of 12 November 2026. The shares closed at $12.44 on 23 October 2026, the 52-week closing low.
• Rebound faded. The shares closed at $16.54 on 9 November 2026 and $15.91 on 11 November 2026, then fell to $14.65 on 12 November 2026. No company news explains the move.
• Control history. The 20-F notes past material weaknesses in internal controls. Law firms have investigated the March 2026 right-of-use restatement since March 2026, and no filed class action had been observed as of 14 October 2026.

Price setup

Adjusted daily closes show $14.22 on 5 November 2026, $14.10 on 6 November 2026, a jump to $16.54 on 9 November 2026, then $15.77, $15.91 and $14.65 on the next three sessions. The shares have a close above the 50-day average of $16.85 in that span.

The 200-day average of $28.60 sits far above the price. A close above the 50-day average would be the first reclaim of a major average since the August decline, when the shares were at $23.57 on 14 August 2026.

The only recent share issuance is the 5 November 2026 conversion of remuneration rights, a small administrative item. No SEC Form 4 insider filings appear among the company's recent filings; the latest SEC filing is the 20-F of 29 September 2026. The next scheduled financial report is the December-quarter cash report, expected near the end of January 2027.

Catalysts ahead

• ~31 December 2026 (est.): Second Elnik HSPT sintering furnace commissioning, scheduled by the company for the December quarter. Shows whether powder output converts into finished parts that can generate customer receipts.
• ~30 January 2027 (est.): December-quarter Appendix 4C/5B cash report. Next scheduled test of customer receipts and cash burn against US$63.0 million of cash at 30 September 2026.

What would change the view

A daily close above $20.05, well over the 50-day average of $16.85, which would show the shares leading the S&P 500. A signed Titan financing package would also show the case failing.

What it trades with

IperionX trades as a single-company story in US titanium and defense supply chains. Its moves have followed its own filings and financing news more than sector indexes. The ASX listing (IPX.AX) opens each US session against overnight Australian pricing, and one ADS represents 10 ordinary shares.